Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes

Pediatric Diabetes

Volumn 17, Issue 4, 2016, Pages 237-243

  Dimeglio, Linda A ^a   Cheng, Peiyao ^b   Beck, Roy W ^b   Kollman, Craig ^b   Ruedy, Katrina J ^b   Slover, Robert ^c   Aye, Tandy ^d   Weinzimer, Stuart A ^e   Bremer, Andrew A ^f   Buckingham, Bruce ^d  

^a INDIANA UNIVERSITY   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e YALE UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical science; Diabetes in childhood; Insulin secretions in vivo

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DRUG EFFICACY; ENDOCRINE PANCREAS FUNCTION TEST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MIXES MEAL TOLERANCE TEST; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; MIDDLE AGED; YOUNG ADULT;

EID: 84969822556     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12271     Document Type: Article

References (20)

1. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003: 26: 832-836.
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. a randomized, controlled trial. Ann Intern Med 1998: 128: 517-523.
3. Buckingham B, Beck RW, Ruedy KJ et al. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care 2013: 36: 4030-4035.
4. Gitelman SE, Gottlieb PA, Rigby MR et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013: 1: 306-316.
5. Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011: 378: 412-419.
6. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009: 361: 2143-2152.
7. Rigby MR, DiMeglio LA, Rendell MS et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013: 1: 284-294.
8. Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011: 378: 319-327.
9. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008: 31: 1966-1971.
10. The Diabetes Control and Complications Trial Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986: 35: 530-545.
11. Palmer J, Fleming G, Greenbaum C et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Diabetes 2004: 53: 250-264. Erratum: Diabetes 2004; 53:1934.
12. Besser REJ, Shields BM, Casas R, Hattersley AT, Ludvigsson J. Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013: 36: 195-201.
13. Akirav E, Kushner JA, Herold KC. β-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008: 57: 2883-2888.
14. Ludvigsson J, Carlsson A, Deli A et al. Decline of C-peptide during the first year after diagnosis of type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 2013: 100: 203-209.
15. The Diabetes Control and Complications Trial Research Group. Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: a multicenter study. Clin Chem 1987: 33: 2267-2271.
16. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes 1978: 27 (Suppl 1): 230-234.
17. Madsbad S, Krarup T, Faber OK, Binder C, Regeur L. The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1982: 22: 16-20.
18. Linn T, Ebener K, Raptis G, Laube H, Federlin K. Natural course of insulin sensitivity and insulin reserve in early insulin-dependent diabetes mellitus. Metabolism 1995: 44: 617-623.
19. Mortensen HB, Swift PGF, Holl RW et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010: 11: 218-226.
20. Greenbaum CJ, Beam CA, Boulware D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012: 61: 2066-2073.